282 related articles for article (PubMed ID: 27864841)
1. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
Hwang YJ; Youn SW; Kim BR; Yu DY; Kim Y; Pires A; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
J Dermatol; 2017 May; 44(5):560-566. PubMed ID: 27864841
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of ustekinumab for treatment of moderate to severe psoriasis: a prospective study in a clinical setting.
Molina-Leyva A; Husein-Elahmed H; Naranjo-Sintes R; Ruiz-Carrascosa JC
J Drugs Dermatol; 2014 Aug; 13(8):971-4. PubMed ID: 25116977
[TBL] [Abstract][Full Text] [Related]
3. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
Takahashi N; Noda S; Taniguchi T; Adachi M
Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital.
Elberdín L; Fernández-Torres R; Paradela S; Blanco E; Outeda M; Martín I; Fonseca E
J Dermatolog Treat; 2020 Nov; 31(7):698-701. PubMed ID: 30961404
[No Abstract] [Full Text] [Related]
6. Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.
van Vugt LJ; van den Reek JMPA; Hannink G; Coenen MJH; de Jong EMGJ
JAMA Dermatol; 2019 Jun; 155(6):708-715. PubMed ID: 30994858
[TBL] [Abstract][Full Text] [Related]
7. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
Chiu HY; Chu TW; Cheng YP; Tsai TF
PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
[TBL] [Abstract][Full Text] [Related]
10. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and
Kim SJ; Park MY; Pak K; Han J; Kim GW; Kim HS; Ko HC; Kim MB; Kim BS
J Dermatolog Treat; 2018 Dec; 29(8):761-768. PubMed ID: 29658378
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of ustekinumab for moderate-to-severe psoriasis: A 9-year real-life experience from a tertiary referral center in Turkey.
Babuna Kobaner G; Polat Ekinci A; Kutlay A
Dermatol Ther; 2021 Jul; 34(4):e15042. PubMed ID: 34161621
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis.
Raposo I; Bettencourt A; Leite L; Selores M; Torres T
Acta Med Port; 2019 Mar; 32(3):214-218. PubMed ID: 30946793
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
14. A real life experience with ustekinumab: The effectiveness of 45 mg on patients greater than 80 kg but lower than 100 kg.
Koç Yıldırım S; Demirel Öğüt N; Erbağcı E; Hapa FA
Dermatol Ther; 2022 Jun; 35(6):e15494. PubMed ID: 35384189
[TBL] [Abstract][Full Text] [Related]
15. Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis.
Romero-Jimenez RM; Escudero-Vilaplana V; Baniandres Rodriguez O; García Martín E; Mateos Mayo A; Sanjurjo Saez M
J Dermatolog Treat; 2018 Dec; 29(8):792-796. PubMed ID: 29676189
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab in clinical practice: response depends on dose and previous treatment.
Ruiz Salas V; Puig L; Alomar A
J Eur Acad Dermatol Venereol; 2012 Apr; 26(4):508-13. PubMed ID: 22077903
[TBL] [Abstract][Full Text] [Related]
17. Genome-Wide Association Study of Ustekinumab Response in Psoriasis.
Connell WT; Hong J; Liao W
Front Immunol; 2021; 12():815121. PubMed ID: 35154085
[TBL] [Abstract][Full Text] [Related]
18. A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment.
Beroukhim K; Danesh M; Nguyen C; Farahnik B; Levin E; Leon A; Koo J
J Dermatolog Treat; 2016 Nov; 27(6):552-555. PubMed ID: 27052387
[TBL] [Abstract][Full Text] [Related]
19. Body Mass Index, Disease Duration and Tumor Necrosis Factor Inhibitor History Predict Reduced Ustekinumab Response in Chinese Psoriasis Patients: A Real-World Study.
Xu X; Qin G; Meng Z; Pei D
Indian J Dermatol; 2021; 66(5):574. PubMed ID: 35068529
[TBL] [Abstract][Full Text] [Related]
20. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.
Savage L; Goodfield M; Horton L; Watad A; Hensor E; Emery P; Wakefield R; Wittmann M; McGonagle D
Arthritis Rheumatol; 2019 Apr; 71(4):626-631. PubMed ID: 30468001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
